Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program
- 27 October 2016
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 33 (2) , 185-191
Abstract
Objective: The introduction of the Hospital Readmission Reduction Program (HRRP) has led to renewed interest in developing strategies to reduce 30 day readmissions among patients with heart failure (HF). In this study, a model was developed to investigate whether the addition of ivabradine to a standard-of-care (SoC) treatment regimen for patients with HF would reduce HRRP penalties incurred by a hypothetical hospital with excess 30 day readmissions. Research design: A model using a Monte Carlo simulation framework was developed. Model inputs included national hospital characteristics, hospital-specific characteristics, and the ivabradine treatment effect as quantified by a post hoc analysis of the Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT). Results: The model computed an 83% reduction in HF readmission penalty payments in a hypothetical hospital with a readmission rate of 22.95% (excess readmission ratio = 1.056 over the national average readmission rate of 21.73%), translating into net savings of $44,016. A sensitivity analysis indicated that the readmission penalty is affected by the specific characteristics of the hospital, including the readmission rate, size of the ivabradine-eligible population, and ivabradine utilization. Conclusions: The results of this study indicate that the addition of ivabradine to an SoC treatment regimen for patients with HF may lead to a reduction in the penalties incurred by hospitals under the HRRP. This highlights the role ivabradine can play as part of a wider effort to optimize the care of patients with HF.Keywords
This publication has 18 references indexed in Scilit:
- Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissionsBMJ, 2013
- Drug Therapy to Reduce Early Readmission Risk in Heart FailureJACC: Heart Failure, 2013
- Rehospitalization for Heart FailureJACC, 2013
- Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT StudyEuropean Heart Journal, 2012
- Contemporary Evidence About Hospital Strategies for Reducing 30-Day ReadmissionsJACC, 2012
- Diuretics and Ultrafiltration in Acute Decompensated Heart FailureJACC, 2012
- Interventions to Reduce 30-Day Rehospitalization: A Systematic ReviewAnnals of Internal Medicine, 2011
- Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT studyEuropean Heart Journal, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery diseaseEuropean Heart Journal, 2005